- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Daratumumab, Echocardiography, Fludarabine, Hematopoietic Cell Transplantation, Indium In 111-DOTA-Daratumumab, Melphalan, Multigated Acquisition Scan, Radionuclide Imaging, Single Photon Emission Computed Tomography, Sirolimus, Tacrolimus, Total Marrow and Lymphoid Irradiation
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 3,167
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia
- Interventions
- carfilzomib, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate, cytarabine, leucovorin calcium, methylprednisolone, rituximab, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- Mehrdad Abedi, MD
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Kidney Failure, Chronic
- Interventions
- IdeS, Kidney transplantation
- Drug · Procedure
- Lead sponsor
- Hansa Biopharma AB
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Baltimore, Maryland • New York, New York
- Conditions
- Hyperkalemia
- Interventions
- Patiromer
- Drug
- Lead sponsor
- Vifor Pharma, Inc.
- Industry
- Eligibility
- 0 Years to 11 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 13
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Miami, Florida + 10 more
- Conditions
- Infections, Papillomavirus, Papillomavirus Vaccines
- Interventions
- CervarixTM, HPV investigational vaccine GSK568893A, different formulations
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 25 Years · Female only
- Enrollment
- 383 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Golden, Colorado • Salt Lake City, Utah
- Conditions
- Food Allergy
- Interventions
- Omalizumab, Food Flour Buildup
- Drug
- Lead sponsor
- Kari Christine Nadeau
- Other
- Eligibility
- 4 Years to 55 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Mountain View, California • Chicago, Illinois + 4 more
- Conditions
- Opioid-Related Disorders, Substance-Related Disorders
- Interventions
- 10% N2O, 20% N2O, 30% N2O, 40% N2O
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 21 Years to 37 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1994 – 1996
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute Coronary Syndrome (ACS)
- Interventions
- Apixaban, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1,741 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 30
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Santa Rosa, California + 27 more
- Conditions
- Solid Tumor, Cancer, Carcinoma
- Interventions
- KHK2455, Mogamulizumab
- Drug
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Albuquerque, New Mexico • Houston, Texas
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- gemcitabine hydrochloride, alvocidib, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Allopurinol, Keppra, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplant, Filgrastim, antithymocyte globulin
- Drug · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 44 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Noise Induced Hearing Loss
- Interventions
- SPI-1005 200mg, SPI-1005 400mg, Placebo
- Drug
- Lead sponsor
- Sound Pharmaceuticals, Incorporated
- Industry
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 5
- States / cities
- Miami, Florida • Kansas City, Kansas • Charleston, South Carolina + 2 more
- Conditions
- COVID-19, Coronavirus, SARS-CoV2 Infection
- Interventions
- Rayaldee, Placebo
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 10
- States / cities
- San Francisco, California • Miami, Florida • Evanston, Illinois + 6 more
- Conditions
- Recurrent Pericarditis
- Interventions
- RPH-104, Placebo
- Biological · Drug
- Lead sponsor
- R-Pharm Overseas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Neoplasm
- Interventions
- SGT-94
- Genetic
- Lead sponsor
- SynerGene Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Influenza
- Interventions
- GSK influenza virus H5N1 vaccine 1557484A
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Bethesda, Maryland • Silver Spring, Maryland
- Conditions
- Volunteers, Healthy
- Interventions
- Recombinant human plasma gelsolin, placebo
- Drug · Other
- Lead sponsor
- BioAegis Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Breast Cancer
- Interventions
- Vitamin D
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Anemia
- Interventions
- Oral iron tablets, VIT-45
- Drug
- Lead sponsor
- American Regent, Inc.
- Industry
- Eligibility
- Female only
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Norristown, Pennsylvania
- Conditions
- Arthritis, Juvenile
- Interventions
- Golimumab, Methotrexate
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 14
- States / cities
- San Diego, California • Chicago, Illinois • Boston, Massachusetts + 11 more
- Conditions
- Meningitis, Meningococcal
- Interventions
- rLP2086 vaccine, control
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 5,715 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 39
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more
- Conditions
- Hyperglycemia Steroid-induced, Insulin Resistance, Diabetes
- Interventions
- NPH Insulin, glargine, Insulin Aspart
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Blood Cancer, Multiple Myeloma
- Interventions
- Autologous hematopoietic cell transplant (Auto-HCT), Allogeneic hematopoietic cell transplant (Allo-HCT), Cyclophosphamide, Filgrastim, Melphalan, Total body irradiation (TBI), Cyclosporine (CSP), Mycophenolate Mofetil (MMF)
- Procedure · Drug · Radiation
- Lead sponsor
- Wen-Kai Weng
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2010
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Influenza
- Interventions
- FluLaval® Quadrivalent, Fluzone®
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Months to 35 Months
- Enrollment
- 316 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 12
- States / cities
- Sacramento, California • West Covina, California • Altamonte Springs, Florida + 9 more